Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malachi Griffith

Showing results (131-140 of 164) with videos related to

Pageof 17
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
JCO Precision Oncology|April 20, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid CorrelatesDaniel A King, Amber R Smith, Gino Pineda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Nature Communications|November 16, 2018
Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Cancer Research Communications|November 1, 2023
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin LymphomaFelicia Gomez, Bryan Fisk, Joshua F McMichael, et al.
Genome Medicine|November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patientsXiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Blood Advances|May 7, 2024
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphomaCody A Ramirez, Michelle Becker-Hapak, Kartik Singhal, et al.
Pageof 17

Showing results (131-140 of 164) with videos related to

Sort By:
Pageof 17
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast CancerCynthia X Ma, Feng Gao, Jingqin Luo, et al.
Nature Communications|September 19, 2018
Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancerAlex H Wagner, Siddhartha Devarakonda, Zachary L Skidmore, et al.
JCO Precision Oncology|April 20, 2023
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid CorrelatesDaniel A King, Amber R Smith, Gino Pineda, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 7, 2017
A Phase II Trial of Neoadjuvant MK-2206, an AKT Inhibitor, with Anastrozole in Clinical Stage II or III <i>PIK3CA</i>-Mutant ER-Positive and HER2-Negative Breast CancerCynthia X Ma, Vera Suman, Matthew P Goetz, et al.
Genome Biology|August 11, 2010
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitorsSteven Jm Jones, Janessa Laskin, Yvonne Y Li, et al.
Nature Communications|September 6, 2018
The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Nature Communications|November 16, 2018
Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancerObi L Griffith, Nicholas C Spies, Meenakshi Anurag, et al.
Cancer Research Communications|November 1, 2023
Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin LymphomaFelicia Gomez, Bryan Fisk, Joshua F McMichael, et al.
Genome Medicine|November 14, 2024
Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patientsXiuli Zhang, S Peter Goedegebuure, Michael Y Chen, et al.
Blood Advances|May 7, 2024
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphomaCody A Ramirez, Michelle Becker-Hapak, Kartik Singhal, et al.
Pageof 17